Apremilast, an Oral Phosphodiesterase 4 Inhibitor, Is Associated with Long-Term (52-Week) Improvements in Enthesitis and Dactylitis in Patients with Psoriatic Arthritis: Results from a Phase 3, Randomized, Controlled Trial

被引：0
|
作者：
Edwards, Christopher J. [1 ]
Aelion, Jacob A. [2 ]
Adebajo, Adewale O. [3 ]
Kivitz, Alan [4 ]
Bird, Paul [5 ]
Hu, ChiaChi [6 ]
Stevens, Randall M. [6 ]
Wells, Alvin [7 ]
机构：
[1] Southampton Univ Hosp, Southampton, Hants, England
[2] West Tennessee Res Inst, Jackson, TN USA
[3] Univ Sheffield, Sheffield, S Yorkshire, England
[4] Altoona Arthrit & Osteoporosis Ctr, Duncansville, PA USA
[5] Combined Rheumatol Practice, Kogarah, NSW, Australia
[6] Celgene Corp, Warren, NJ USA
[7] Rheumatol & Immunotherapy Ctr, Franklin, WI USA
来源：
ARTHRITIS & RHEUMATOLOGY | 2014年 / 66卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1572
引用
收藏
页码：S694 / S695
页数：2
相关论文
共 50 条
  • [21] Apremilast, An Oral Phosphodiesterase 4 Inhibitor, Is Associated With Long-Term (52-Week) Improvement In Physical Function In Patients With Psoriatic Arthritis: Results From Three Phase 3, Randomized, Controlled Trials
    Schett, Georg
    Mease, Philip J.
    Gladman, Dafna D.
    Kavanaugh, Arthur
    Adebajo, Adewale O.
    Gomez-Reino, Juan J.
    Wollenhaupt, Juergen
    Cutolo, Maurizio
    Lespessailles, Eric
    Shah, Kamal
    Hu, ChiaChi
    Stevens, Randall M.
    Edwards, Christopher J.
    Birbara, Charles A.
    [J]. ARTHRITIS AND RHEUMATISM, 2013, 65 : S143 - S143
  • [22] APREMILAST, AN ORAL PHOSPHODIESTERASE 4 INHIBITOR, IS ASSOCIATED WITH LONG-TERM (104-WEEK) IMPROVEMENTS IN ENTHESITIS AND DACTYLITIS IN PATIENTS WITH PSORIATIC ARTHRITIS: POOLED RESULTS FROM THREE PHASE III, RANDOMISED, CONTROLLED TRIALS
    Dafna, Gladman
    Stephen, Hall
    Arthur, Kavanaugh
    Adewale, Adebajo
    Juan, Gomez-Reino
    Jurgen, Wollenhaupt
    Maurizio, Cutolo
    Eric, Lespessailles
    Melissa, Mcllraith
    Chiachi, Hu
    Christopher, Edwards
    Charles, Birbara
    Philip, Mease
    [J]. INTERNAL MEDICINE JOURNAL, 2016, 46 : 22 - 23
  • [23] Apremilast, an Oral Phosphodiesterase 4 Inhibitor, Is Associated with Long-Term (52-Week) Improvement in the Signs and Symptoms of Psoriatic Arthritis in DMARD-Naive Patients: Results from a Phase 3, Randomized, Controlled Trial
    Wells, Alvin
    Adebajo, Adewale O.
    Aelion, Jacob A.
    Bird, Paul
    Kivitz, Alan
    Liote, Frederic
    Sarzi-Puttini, Piercarlo
    Hu, ChiaChi
    Stevens, Randall M.
    Edwards, Christopher J.
    [J]. ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S680 - S680
  • [24] APREMILAST, AN ORAL PHOSPHODIESTERASE 4 INHIBITOR, IS ASSOCIATED WITH LONG-TERM (52-WEEK) IMPROVEMENT IN MEASURES OF DISEASE ACTIVITY IN PATIENTS WITH PSORIATIC ARTHRITIS: RESULTS FROM 3 PHASE 3, RANDOMIZED, CONTROLLED TRIALS
    Kavanaugh, A.
    Cutolo, M.
    Mease, P.
    Gladman, D.
    Adebajo, A.
    Gomez-Reino, J.
    Wollenhaupt, J.
    Schett, G.
    Lespessailles, E.
    Hu, C.
    Stevens, R.
    Edwards, C.
    Birbara, C.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 90 - 91
  • [25] Apremilast, an Oral Phosphodiesterase 4 Inhibitor, is Associated with Longterm (52-Week) Improvements in BASDAI in Patients with Psoriatic Arthritis: Pooled Results from 3 Phase III, Randomized, Controlled Trials
    Mease, Philip
    Marzo-Ortega, Helena
    Poder, Airi
    van den Bosch, Filip
    Wollenhaupt, Juergen
    Lespessailles, Eric
    McIlraith, Melissa
    Teng, Lichen
    Gladman, Dafna
    Hall, Stephen
    [J]. JOURNAL OF RHEUMATOLOGY, 2017, 44 (06) : 925 - 926
  • [26] Apremilast, an Oral Phosphodiesterase 4 Inhibitor, Is Associated with Long-Term (52-Week) Improvement in Measures of Disease Activity in Patients with Psoriatic Arthritis: Results from 3 Phase 3, Randomized, Controlled Trials.
    Kavanaugh, Arthur
    Cutolo, Maurizio
    Mease, Philip
    Gladman, Dafna D.
    Adebajo, Adewale O.
    Gomez-Reino, Juan
    Wollenhaupt, Juergen
    Schett, Georg A.
    Lespessailles, Eric
    Hu, ChiaChi
    Stevens, Randall M.
    Edwards, Christopher
    Birbara, Charles A.
    [J]. ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S239 - S240
  • [27] Apremilast, An Oral Phosphodiesterase 4 Inhibitor, Is Associated With Long-Term (52-Week) Improvement In Tender and Swollen Joint Counts In Patients With Psoriatic Arthritis: Results From Three Phase 3, Randomized, Controlled Trials
    Cutolo, Maurizio
    Mease, Philip J.
    Gladman, Dafna D.
    Kavanaugh, Arthur
    Adebajo, Adewale O.
    Gomez-Reino, Juan J.
    Wollenhaupt, Juergen
    Schett, Georg
    Lespessailles, Eric
    Shah, Kamal
    Hu, ChiaChi
    Stevens, Randall M.
    Edwards, Christopher J.
    Birbara, Charles A.
    [J]. ARTHRITIS AND RHEUMATISM, 2013, 65 : S135 - S136
  • [28] Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis: results of a phase 3, randomized, controlled trial
    Kavanaugh, Arthur
    Mease, Philip J.
    Gomez-Reino, Juan J.
    Adewale, Adebajo
    Wollenhaupt, Juergen
    Hu, ChiaChi
    Stevens, Randall
    Cutolo, Maurizio
    [J]. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2013, 31 (05) : 832 - 832
  • [29] APREMILAST, AN ORAL PHOSPHODIESTERASE 4 INHIBITOR, IS ASSOCIATED WITH LONG-TERM (156-WEEK) IMPROVEMENTS IN BASDAI IN PSORIATIC ARTHRITIS PATIENTS: POOLED RESULTS FROM 3 PHASE III, RANDOMIZED, CONTROLLED TRIALS
    Mease, P. J.
    Marzo-Ortega, H.
    Poder, A.
    Van den Bosch, F.
    Wollenhaupt, J.
    Lespessailles, E.
    McIlraith, M.
    Teng, L.
    Hall, S.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 683 - 684
  • [30] LONG-TERM SAFETY AND TOLERABILITY OF APREMILAST, AN ORAL PHOSPHODIESTERASE 4 INHIBITOR, IN PATIENTS WITH PSORIATIC ARTHRITIS: A PHASE 3, RANDOMIZED, CONTROLLED TRIAL
    Adebajo, A.
    Wells, A.
    Edwards, C.
    Kivitz, A.
    Bird, P.
    Shah, K.
    Hu, C.
    Stevens, R.
    Aelion, J.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 730 - 730
12345